Metropolitan Life Insurance CO Viracta Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$3.37 - $7.91 $19,431 - $45,609	-5,766 Closed	0 $0
Q3 2021 Jun 21, 2023	BUY	$7.84 - $12.53 $45,205 - $72,247	5,766 New	5,766 $46,000
Q3 2021 Mar 30, 2023	SELL	$7.84 - $12.53 $43,072 - $68,839	-5,494 Reduced 48.79%	5,766 $46,000
Q3 2021 Nov 15, 2021	SELL	$7.84 - $12.53 $43,072 - $68,839	-5,494 Reduced 48.79%	5,766 $46,000
Q2 2021 Jun 21, 2023	BUY	$7.55 - $12.95 $85,013 - $145,817	11,260 New	11,260 $127,000
Q2 2021 Mar 30, 2023	BUY	$7.55 - $12.95 $85,013 - $145,817	11,260 New	11,260 $127,000
Q2 2021 Aug 16, 2021	BUY	$7.55 - $12.95 $85,013 - $145,817	11,260 New	11,260 $128,000

5.63M

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $7.51M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.